CL2023003533A1 - Métodos para tratar el cáncer de mama - Google Patents
Métodos para tratar el cáncer de mamaInfo
- Publication number
- CL2023003533A1 CL2023003533A1 CL2023003533A CL2023003533A CL2023003533A1 CL 2023003533 A1 CL2023003533 A1 CL 2023003533A1 CL 2023003533 A CL2023003533 A CL 2023003533A CL 2023003533 A CL2023003533 A CL 2023003533A CL 2023003533 A1 CL2023003533 A1 CL 2023003533A1
- Authority
- CL
- Chile
- Prior art keywords
- breast cancer
- methods
- treating breast
- subject
- adjuvant
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 3
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 102000036365 BRCA1 Human genes 0.000 abstract 1
- 108700020463 BRCA1 Proteins 0.000 abstract 1
- 101150072950 BRCA1 gene Proteins 0.000 abstract 1
- 102000052609 BRCA2 Human genes 0.000 abstract 1
- 108700020462 BRCA2 Proteins 0.000 abstract 1
- 101150008921 Brca2 gene Proteins 0.000 abstract 1
- 238000011226 adjuvant chemotherapy Methods 0.000 abstract 1
- 238000009098 adjuvant therapy Methods 0.000 abstract 1
- 210000004602 germ cell Anatomy 0.000 abstract 1
- 238000011227 neoadjuvant chemotherapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163195795P | 2021-06-02 | 2021-06-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023003533A1 true CL2023003533A1 (es) | 2024-06-28 |
Family
ID=82117716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023003533A CL2023003533A1 (es) | 2021-06-02 | 2023-11-28 | Métodos para tratar el cáncer de mama |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240269135A1 (https=) |
| EP (1) | EP4346828A1 (https=) |
| JP (1) | JP2024520142A (https=) |
| KR (1) | KR20240016344A (https=) |
| CN (1) | CN118139624A (https=) |
| AU (1) | AU2022286616A1 (https=) |
| BR (1) | BR112023025003A2 (https=) |
| CA (1) | CA3220751A1 (https=) |
| CL (1) | CL2023003533A1 (https=) |
| IL (1) | IL308684A (https=) |
| MX (1) | MX2023014420A (https=) |
| WO (1) | WO2022253800A1 (https=) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1633724T3 (pl) | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
-
2022
- 2022-05-31 CA CA3220751A patent/CA3220751A1/en active Pending
- 2022-05-31 US US18/564,778 patent/US20240269135A1/en active Pending
- 2022-05-31 EP EP22732066.0A patent/EP4346828A1/en not_active Withdrawn
- 2022-05-31 KR KR1020237045312A patent/KR20240016344A/ko not_active Withdrawn
- 2022-05-31 MX MX2023014420A patent/MX2023014420A/es unknown
- 2022-05-31 JP JP2023574549A patent/JP2024520142A/ja not_active Withdrawn
- 2022-05-31 WO PCT/EP2022/064697 patent/WO2022253800A1/en not_active Ceased
- 2022-05-31 CN CN202280039309.4A patent/CN118139624A/zh active Pending
- 2022-05-31 BR BR112023025003A patent/BR112023025003A2/pt not_active Application Discontinuation
- 2022-05-31 IL IL308684A patent/IL308684A/en unknown
- 2022-05-31 AU AU2022286616A patent/AU2022286616A1/en not_active Abandoned
-
2023
- 2023-11-28 CL CL2023003533A patent/CL2023003533A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024520142A (ja) | 2024-05-21 |
| CA3220751A1 (en) | 2022-12-08 |
| MX2023014420A (es) | 2024-04-23 |
| CN118139624A (zh) | 2024-06-04 |
| WO2022253800A1 (en) | 2022-12-08 |
| US20240269135A1 (en) | 2024-08-15 |
| KR20240016344A (ko) | 2024-02-06 |
| BR112023025003A2 (pt) | 2024-02-20 |
| AU2022286616A1 (en) | 2024-01-18 |
| IL308684A (en) | 2024-01-01 |
| EP4346828A1 (en) | 2024-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024001473A1 (es) | Conjugados de fármacos y anticuerpos anti-ccr7 | |
| CL2019002304A1 (es) | Compuestos para el tratamiento del cáncer. | |
| CU20210098A7 (es) | Derivados de quinazolin-4-one útiles para el tratamiento de enfermedades y trastornos asociados con braf | |
| MX2021004881A (es) | Combinacion de palbociclib y rad1901 para usarse en el tratamiento de cancer de mama en un sujeto con cancer positivo a receptor de estrogeno. | |
| ECSP19083967A (es) | Compuestos antitumorales | |
| MX2019014021A (es) | Derivado de n-(azaarilo)ciclo lactam-1-carboxamida, metodo de preparacion del mismo y uso del mismo. | |
| MY198613A (en) | Nitrobenzyl derivatives of anti-cancer agents | |
| NI201000083A (es) | Tratamiento de cáncer de mama con un compuesto de 4 - iodo - 3 - nitrobenzamida en combinación con agentes anti-tumorales. | |
| ECSP17005635A (es) | Inhibidores de desmetilasa-1 específica a lisina | |
| CO2017002191A2 (es) | Inhibidores de desmetilasa-1 específica a lisina | |
| MX2022007974A (es) | Metodos de tratamiento del cancer con anticuerpos anti-cd70 no fucosilados. | |
| MX2023008327A (es) | Anticuerpos inmunomoduladores de anticuerpo-farmaco. | |
| CO2024009571A2 (es) | Inhibidores de parp1 | |
| CO2017002772A2 (es) | Inhibidores de histona desmetilasa | |
| MX2019009304A (es) | Tratamiento para el cancer. | |
| NI201900009A (es) | MÃTODOS PARA TRATAR EL CÃNCER DE PRÃSTATA Se describen métodos para tratar el c | |
| EA201991818A1 (ru) | Лечение рака | |
| PE20180454A1 (es) | Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2 | |
| PH12017501879A1 (en) | Methods for treating cancer | |
| MX2020012291A (es) | Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario. | |
| AR119681A1 (es) | Métodos de tratamiento del cáncer de mama con tucatinib | |
| DOP2023000142A (es) | Quinolinas y azaquinolinas como inhibidores de cd38 | |
| BR112022001045A2 (pt) | Método para tratar um indivíduo com ou em risco de desenvolver um câncer associado a liv1, e, kit | |
| MX2021009182A (es) | Antiandrogenos para el tratamiento de cancer de prostata metastasico sensible a la castracion. | |
| MX2019009356A (es) | Sulfinilpiridinas y su uso en el tratamiento del cancer. |